abciximab

Known as: 7E3, abciximab [Chemical/Ingredient], C7E3 
A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND The glycoprotein IIb/IIIa receptor inhibitor abciximab has improved the efficacy of primary percutaneous coronary… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Thrombolysis remains the treatment of choice in ST-segment elevation myocardial infarction (STEMI) when primary… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
CONTEXT The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
A BSTRACT Background As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in… (More)
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
OBJECTIVES We sought to determine whether abciximab therapy at the time of percutaneous coronary intervention (PCI) would… (More)
  • figure 2
  • table 1
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
BACKGROUND The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
BACKGROUND In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces… (More)
Is this relevant?